Veröffentlichungen

• Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study

  Claire Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Sophie Biguenet, Didier Scherrer, Julien Santo, Hartmut Ehrlich, Patrick Durez
  Annals of the Rheumatic Disease, June 2022, in print.

• Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: Results of phase 2a trial

  Severine Vermeire, Xavier Hébuterne, Herbert Tilg, Gert De Hertogh, Paul Gineste, Jean-Marc Steens
  Gastroenterology, Volume 160, Issue 7, June 2021, P. 2595-2598.E3

• Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases

  Jamal Tazi, Christina Begon-Pescia, Noëlie Campos, Cécile Apolit, AudeGarcel, DidierScherrer
  Drug Discovery Today, Volume 26, Issue 4, April 2021, P. 1030-1039

• Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing

  Audrey Vautrin, Laurent Manchon, Aude Garcel, Noëlie Campos, Laure Lapasset, Abdelhamid Mahdi Laaref, Roman Bruno, Marie Gislard, Emeric Dubois, Didier Scherrer, Hartmut Ehrlich and Jamal Tazi
  Nature Scientific Report, Band 9, Artikelnummer: 792, Januar 2019

• The Anti-Hiv Candidate Abx464 Dampens Intestinal Inflammation by Triggering Il-22 Production in Activated Macrophages

  Karim Chebli, Laura Papon, Conception Paul, Aude Garcel, Noëlie Campos, Didier Scherrer, Hartmut J. Ehrlich, Michael Hahne & Jamal Tazi
  Nature Scientific Report, Band 7, Artikelnummer: 4860, Juli 2017

• Pharmacokinetics And Tolerability of ABX464, A Novel First-in-Class Compound To Treat HIV Infection, In Healthy HIV-uninfected Subjects.

  Scherrer D, Rouzier R, Noel Barrett P, Steens JM, Gineste P, Murphy RL, Tazi J, Ehrlich HJ.
  Journal of Antimicrobial Chemotherapy, Band 72, Ausgabe 3, März 2017

• Randomized Trial of Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects.

  Scherrer D, Rouzier R, Cardona M, Barrett PN, Steens JM, Gineste P, Murphy RL, Tazi J, Ehrlich HJ.
  Antimicrobial Agents and Chemotherapy, Band 61, Ausgabe 1, Januar 2017

• Differential Efficacy of ABX464 and Its Primary Metabolite ABX464- Nglc on Hiv Replication In Human Pbmc’s and Macrophages: Implications for Treatment Strategies to Eliminate Virus Reservoirs

  D. Scherrer, J.-M. Steens, P. Gineste, N. Campos, A. Garcel, E. Schlaefper, R. Speck, J. Tazi, H.J. Ehrlich
  Präsentation: HIV Drug Conference, Oktober 2016

• Early Evidence of Antiviral Activity and Safety of ABX464 in HIV Treatment Naïve Patient

  Didier Scherrer, Jean-Marc Steens, Supparatpinyo Kuanchai, Ratanasuwan Winai, Kiat Ruxrungtham, Regine Rouzier, Jamal Tazi, Paul Gineste, Hartmut Ehrlich, Robert Murphy
  Präsentation: Konferenz über Retroviren und opportunistische Infektionen, Februar 2016

• Long Lasting Control of Viral Rebound with a New Drug ABX464 Targeting Rev – Mediated Viral RNA Biogenesis

  N. Campos, R. Myburgh, A. Garcel, A. Vautrin, L. Lapasset, E. Schläpfer Nadal, F. Mahuteau-Betzer, R. Najman, P. Fornarelli, K Tantale, E. Basyuk, M. Séveno, J. Venables, B.Pau, E. Bertrand, M. Wainberg, R.Speck, D. Scherrer and J. Tazi
  Retrovirology, Volume 12, Issue 30 März 2015

• Durable Control of Viral Load Rebound In Humanized Mice By ABX464 Targeting Rev Functions

  Noelie Campos, Renier Myburgh, Aude Garcel, Audrey Vautrin, Laure Lapasset, Katjana Tantale, Mark Wainberg, Roberto Speck, Didier Scherrer, Jamal Tazi
  Präsentation: Konferenz über Retroviren und opportunistische Infektionen Februar 2015